Cilengitide, a cyclic RGD peptide integrin inhibitor with great safety and tolerance, can decrease the expression of integrin αvβ3 and αvβ5 and inhibit the FAK/Src/Akt signaling pathway, thus triggering apoptosis in glioblastoma, HNSCC and laryngeal cancer cells (Ellert-Miklaszewska et al., 2020; Li et al., 2019; Liu et al., 2023b; Stupp et al., 2014). The gene discussed is PTK2; the disease is glioblastoma.